Hospitalization and Continuity of Care in Anti-MDA5 Dermatomyositis

William Mark Richardson,Jill T. Shah,Daniel R. Mazori,Avrom S. Caplan,Kristen I. Lo Sicco,Alisa N. Femia

DOI: https://doi.org/10.1001/jamadermatol.2024.0403

IF: 11.816

2024-04-17

JAMA Dermatology

Abstract:This cohort study describes the clinical features, patient characteristics, and treatment of anti-melanoma differentiation–associated gene 5 (MDA5) dermatomyositis.

dermatology

What problem does this paper attempt to address?

Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review

Kun Huang,Ophir Vinik,Kam Shojania,James Yeung,Rachel Shupak,Michael Nimmo,J. Antonio Avina-Zubieta

DOI: https://doi.org/10.1007/s00296-019-04398-2

2019-08-02

Rheumatology International

Abstract:The objective of the study was to determine the clinical features and treatment course in Canadian patients with dermatomyositis (DM) associated with the anti-melanoma differentiation-associated gene 5 antibody (MDA5). A retrospective chart review of consecutive patients with anti-MDA5 antibody DM from two Canadian tertiary care centre between 2014 and 2018 was done. Twenty-one consecutive cases of anti-MDA5-positive DM were identified. Median age at diagnosis was 52 years, 71% Asians, predominantly Chinese, and 29% Caucasians. In this case series, all patients had either typical DM rash, or vasculopathy and ulceration unique to anti-MDA5-positive DM. 38% of the patients had rapid progressive (RP)-interstitial lung disease (RP-ILD), 33% had chronic ILD and 29% had asymptomatic ILD. Anti-Ro52 positivity was more prevalent in RP-ILD. Mortality was high in the RP-ILD group, with five deaths in eight patients. Lung transplant was life-saving intervention for three of the RP-ILD patients who survived. A review of the literature in treating RP-ILD associated with anti-MDA5 is presented. Although evidence is limited to small case series, cyclophosphamide (CYC) for refractory skin lesions, and CYC or mycophenolate mofetil plus a calcineurin inhibitor or rituximab (RTX) for RP-ILD appear efficacious. This is the largest North American case series of anti-MDA5-positive DM patients to date. There is a wide spectrum of clinical presentation of this entity. Survival is poor in those with RP-ILD; early aggressive immunosuppression and timely lung transplant were life-saving in our patients with RP-ILD.

rheumatology
Unique Characteristics of Anti-MDA-5 Associated Dermatomyositis in Southern California with a Large Hispanic Population

Eaman Alhassan,Belina Y. Yi,Jack Rodman,Michael H Weisman,Ashley Crew,Leanna Wise

DOI: https://doi.org/10.1016/j.semarthrit.2024.152434

IF: 5.431

2024-03-17

Seminars in Arthritis and Rheumatism

Abstract:Objectives There is little to no data about the presentation and clinical course of anti-melanoma differentiation-associated gene-5 antibody (anti-MDA-5) dermatomyositis in a primarily U.S. Hispanic population. We describe the clinical course of anti-MDA-5 dermatomyositis in our majority Hispanic population. Methods This is a multicenter, retrospective case series of anti-MDA-5 dermatomyositis. Patients diagnosed with anti-MDA-5 dermatomyositis from June 2015 to March 2023 at four medical centers in Los Angeles, California, were included. Demographics and clinical characteristics were obtained. Descriptive statistics, Pearson's chi-squared, Fisher's exact, Wilcoxon rank sum, and Kruskal-Wallis tests were performed as applicable. Results Thirty anti-MDA-5 dermatomyositis patients were included. Twenty-two (73%) were Hispanic. Twenty-one patients (70%) were female, with a median age of 40.5 years. Hispanic patients were diagnosed with anti-MDA-5 dermatomyositis at a younger age than non-Hispanic patients (p=0.025). Inflammatory arthritis was prominent; more males were affected than females (p=0.027). Thirteen patients (43%) were amyopathic. Twenty-five patients (83.3%) had evidence of interstitial lung disease (ILD), and a higher ferritin level was associated with ILD (p=0.049). There were six deaths (20%); five (17%) were ascribed to rapidly progressive ILD. Conclusion ILD was the most common presentation of anti-MDA-5 dermatomyositis in our cohort and was associated with higher ferritin levels. Hispanic patients had a younger age of diagnosis than non-Hispanic patients. Necrotic skin lesions and inflammatory arthritis were frequently seen. This is the first study looking at clinical phenotypes and outcomes of anti-MDA-5 dermatomyositis in a primarily Hispanic U.S. population. Future studies are needed to better understand the clinical manifestations (to promptly recognize and treat) of this population of anti-MDA-5 dermatomyositis.

rheumatology
Patient Perspectives of the Manifestations and Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis: An Observational Survey

Timothy Kaniecki,Benita Moyers,Manuel Lubinus,Yuan-Pai Hu,Lynn Wilson,Stephen Moore,Jerry Williams,Lisa Christopher-Stine

DOI: https://doi.org/10.3899/jrheum.2024-0108

2024-09-03

The Journal of Rheumatology

Abstract:Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune disorders classically characterized by proximal skeletal muscle inflammation leading to weakness, but they often possess additional systemic manifestations such as cutaneous, pulmonary, and articular disease.1 Although originally dichotomized as either dermatomyositis (DM) or polymyositis, the discovery of new myositis-specific antibodies (MSA) and myositis-associated antibodies has led to the delineation of more refined IIM patient subgroups. The antimelanoma differentiation-associated gene 5 (MDA5) MSA is an example, found to define a clinically distinct DM subgroup characterized by hypomyopathic or amyopathic muscle disease, distinct cutaneous features, and increased risk for rapidly progressive interstitial lung disease (RP-ILD).1,2 Many of the cutaneous manifestations of anti-MDA5 antibody–positive DM (anti-MDA5-DM) are unique or atypical when compared to other IIM subtypes. This can have implications for diagnosis and treatment delays. Atypical features include cutaneous ulceration (with a predilection for the nailfolds and overlying Gottron papules/sign), palmar papules (occurring on the palms and palmar aspect of the fingers, particularly within the joint creases), and mechanic hands (fissured, hyperkeratotic plaques along the thenar, radial, and ulnar aspects of the fingers, classically associated with the antisynthetase syndrome), among other more classic DM cutaneous findings.2 The unique clinical features of anti-MDA5-DM and its implications with regard to prognosis, given the association with highly morbid RP-ILD, further stresses the necessity for increased clinician awareness of this rare clinical syndrome so that earlier diagnosis and treatment can be initiated. One such strategy to increase overall clinical awareness of rare disorders is through patient support groups and organizations. Myositis Support and Understanding (MSU) is a nonprofit, patient-led advocacy organization for IIM care teams. MSU identified a need to increase research defining the clinical characteristics of individual DM subtypes and created patient-led research teams to help spearhead this effort, hosting patient ...

rheumatology
Anti‐MDA5 positivity: describing the frequency and spectrum of clinically evident MDA5 disease

Janelle See,Jessica L. Fairley,Ai L. Yeo,Samar Ojaimi,Eric F. Morand

DOI: https://doi.org/10.1111/imj.16563

2024-11-13

Internal Medicine Journal

Abstract:To evaluate experience in a tertiary rheumatology service with melanoma differentiation‐association‐protein‐5 (MDA5) disease and testing, patients with positive autoantibody results were reviewed for the presence of clinical disease. Anti‐MDA5 positivity was detected in 2% of myositis‐specific antibody tests. Of these, 29% did not have features consistent with anti‐MDA5 disease. However, when present, MDA5 disease is severe with a high mortality.

medicine, general & internal
Short-term and long-term outcomes of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis

Tomoaki Ida,Shunsuke Furuta,Michio Fujiwara,Masaki Hiraguri,Koichi Hirose,Kei Ikeda,Taro Iwamoto,Shin-Ichiro Kagami,Yoshihisa Kobayashi,Kazuhiro Kurasawa,Daiki Nakagomi,Yoshihiro Oya,Yoshie Sanayama,Toshimasa Shimizu,Tomohiro Tamachi,Takeshi Umibe,Masahiro Yasui,Hiroshi Nakajima

DOI: https://doi.org/10.1093/rheumatology/keae011

2024-01-12

Rheumatology

Abstract:Abstract Objectives Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) is a subtype of dermatomyositis characterized by frequent interstitial lung disease and reduced muscle involvement. This study aimed to determine the short-term and long-term outcomes of patients with MDA5-DM. Methods Information on baseline characteristics, treatments and short-term and long-term outcomes of patients with MDA5-DM including survival, relapse and the titre of anti-MDA5 antibody, was retrospectively collected. Descriptive statistics regarding clinical outcomes were calculated, and a comparison of clinical parameters between patients with and without relapse was performed. The short-term survival according to the use of Janus kinase inhibitors (JAKi) was also assessed. Results A total of 154 patients with MDA5-DM were included in the study. Forty patients (26.0%) died during the remission induction phase, with respiratory failure being the most common cause of mortality. Among the 114 patients who survived the remission induction phase, the 5-year cumulative survival and relapse-free survival rates were 96.8% and 77.4%, respectively, and 7.9% of patients achieved complete drug-free remission. Fifty-four patients achieved normalization of anti-MDA5 antibody titres and only two of them relapsed after normalization. In the severe patients, the 6-month survival rate became significantly higher after the emergence of the JAKi treatment compared with before its existence (P = 0.03). Conclusion Although relapse often occurs, the long-term survival of MDA5-DM patients who survived the remission induction phase is generally favourable. The status of the anti-MDA5 antibody is associated with relapse. JAKi may improve the survival of refractory patients with severe MDA5-DM.

rheumatology
Clinical features of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with macrophage activation syndrome

Lu Yang,Panpan Zhang,Qihua Yang,Chunyi Zhang,Wenjuan Guan,Shengyun Liu

DOI: https://doi.org/10.55563/clinexprheumatol/2537nv

Abstract:Objectives: This study aimed to describe the clinical features of patients with anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis (DM) who had macrophage activation syndrome (MAS). Methods: We retrospectively examined 44 patients with anti-MDA5-positive DM and compared the clinical features between patients with MAS (n = 11) and those without (n=33). Patients without MAS were selected randomly in the same year as those with MAS at a ratio of 3:1. Among patients with MAS, we compared the features between non-survivors and survivors. We used Fisher's exact test, Student's t test, the Mann-Whitney U test and the log-rank test for statistical analysis. Results: Patients complicated with MAS had a significantly higher incidence of infection, heliotrope sign, Gottron's papule, V-neck sign, and higher serum levels of ferritin, aspartate aminotransferase (AST), lactic dehydrogenase (LDH), and creatine kinase (CK) than those without MAS (p<0.05). Among the 11 patients with MAS, 4 (36.4%) died after intensive treatment. Deceased patients were older, given more combination therapy with tofacitinib (TOF) and had a higher incidence of rapid progressive interstitial lung disease, infection, heart failure and renal impairment than those who survived (p<0.05). Conclusions: Among anti-MDA5-positive DM, Infection, DM typical rashes, and higher serum levels of ferritin, AST, LDH, and CK were more common in patients complicated with MAS. The mortality of patients with MAS was high, particularly among patients who were older, given more combination therapy with TOF, and had RP-ILD, infection, heart failure and renal impairment.
Characteristics of anti-melanoma differentiation associated gene 5 antibody-positive dermatomyositis with thrombotic microangiopathy

Toshiyuki Shiki Ushijima,Toshihiko Komai,Shinji Izuka,Hirofumi Shoda,Keishi Fujio

DOI: https://doi.org/10.1093/mr/roae009

2024-02-07

Modern Rheumatology

Abstract:Abstract Objectives: Anti-melanoma differentiation associated gene 5 antibody (anti-MDA5 Ab)-positive dermatomyositis (DM) is representative of rapidly progressive interstitial pneumonia. However, its association with thrombotic microangiopathy (TMA), characterized by thrombocytopenia, hemolytic anemia, and organ dysfunction, has not been defined. This study aimed to elucidate the characteristics of anti-MDA5 Ab-positive DM accompanied by TMA. Methods: We reviewed our hospital records from November 2009 to September 2022. We included patients in accordance with the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria and with the criteria of Bohan and Peter. TMA was diagnosed according to the criteria for transplantation-associated TMA proposed by the International Working Group. Results: This study enrolled a total of 26 anti-MDA5 Ab-positive DM patients, four of whom developed TMA. The patients with TMA had an increased urine protein/creatinine ratio (UPCR). In addition, these four patients showed significantly elevated levels of ferritin and anti-MDA5 Ab titers and were considered to have high disease activity; yet, all of them survived. Conclusions: Out study indicated that anti-MDA5 Ab-positive DM patients with hyperferritinemia, a high anti-MDA5 Ab titer, and an increased UPCR should be carefully managed, bearing in mind a complication of TMA.

rheumatology
Treatment strategies in MDA5-positive clinically amyopathic dermatomyositis: a single-center retrospective analysis

Stefanie Hirsch,Gesa Helen Pöhler,Benjamin Seeliger,Antje Prasse,Torsten Witte,Thea Thiele

DOI: https://doi.org/10.1007/s10238-024-01300-8

IF: 4.6

2024-02-18

Clinical and Experimental Medicine

Abstract:Melanoma differentiation-associated protein 5 (MDA5) antibody positive amyopathic dermatomyositis (DM) is a rare inflammatory disease. So far, there is no official treatment guideline in MDA5 amyopathic dermatomyositis, but early and aggressive immunosuppressive combination treatment can induce a stable remission. We retrospectively analyzed a cohort of eight patients (male n = 5) that were diagnosed with MDA5-positive amyopathic DM. Patient data comprised demographics, CT-guided diagnosis of pulmonary involvement, pulmonary function testing including forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) data on baseline and mean long-term follow-up of 51 months (24–92 months) to evaluate treatment strategies. Depending on severity of organ involvement treatments were individualized including cyclophosphamide, immunoglobulins and plasmapheresis. Simultaneously, oral treatment with tacrolimus was commenced in four of the eight patients. Most patients received remission maintenance therapy with a combination of tacrolimus, rituximab and low dose steroids. In all patients, improvement in FVC was recorded and five patients achieved an improvement in DLCO. An improvement in the CT imaging morphological findings was observed in four patients. Awareness for the entirety of all clinical and disease-related findings of amyopathic DM is crucial, and remission maintenance is often achieved with a combination of tacrolimus and rituximab.

medicine, research & experimental
Myocardial involvement is not rare in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis/clinically amyopathic dermatomyositis: a retrospective study

Shuang Zhou,Jinzhi Lai,Chanyuan Wu,Yongtai Liu,Yingxian Liu,Jiuliang Zhao,Dong Xu,Xinping Tian,Mengtao Li,Yan Zhao,Yining Wang,Qian Wang,Xiaofeng Zeng

DOI: https://doi.org/10.3389/fimmu.2022.928861

IF: 7.3

2022-08-02

Frontiers in Immunology

Abstract:Objectives Studies concerning myocardial involvement (MI) in patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis/clinically amyopathic dermatomyositis (anti-MDA5 Ab+ DM/CADM) are scarce. We aimed to characterize MI in our anti-MDA5 Ab+ DM/CADM cohort and to investigate its association with prognosis. Methods In this single-center retrospective study, anti-MDA5 Ab+ hospitalized DM/CADM patients who underwent transthoracic echocardiography (TTE) were enrolled. Myocardial involvement was diagnosed according to abnormal cardiac structure and function detected by TEE. Clinical features and cardiac examination findings of patients with MI were analyzed. Clinical features, laboratory findings, complications, and treatments were compared between MI and non-MI, deceased, and survival patients. Logistic regression analysis was used to explore the independent risk factors for the occurrence of MI and prognostic factors for these patients. Results Seventy-six hospitalized patients with anti-MDA5 Ab+ DM/CADM were enrolled. Twelve (15.8%) patients were diagnosed with MI. Of the 12 patients, three underwent cardiac magnetic resonance imaging (CMR) and late gadolinium enhancement (LGE) were noted for them. TEE revealed that eight (66.7%) patients had left atrial and/or ventricular enlargement, three (25.0%) had cardiac hypertrophy, six (50.0%) had diffuse ventricular wall dyskinesia, and seven (58.3%) had diastolic dysfunction. Six (50.0%) patients with MI developed heart failure (HF) during treatment. Of the 12 patients, one patient died of HF caused by myocarditis, three died of infection, and four died of exacerbation of rapidly progressive interstitial lung disease (RP-ILD). Logistic regression analysis revealed that dysphagia (OR 3.923, 95% CI 1.085, 14.181), NT-proBNP >600 pg/ml (OR 18.333, 95% CI 1.508, 222.875), and increased peripheral white blood cells (OR 1.201, 95% CI 1.003, 1.438) were risk factors for the occurrence of MI, but plasma albumin (OR 0.892, 95% CI 0.796, 0.999) was a protective factor. Both MI (OR 5.984, 95% CI 1.174, 30.496) and RP-ILD (OR 11.875, 95% CI 2.796, 50.411) were independent risk factors for the mortality of these anti-MDA5 Ab+ DM/CADM patients. Conclusion Myocardial involvement is not rare and is an independent poor prognostic factor of anti-MDA5 Ab+ DM/CADM patients. Cardiac abnormality screening is necessary for them.

immunology
Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease

Sei-ichiro Motegi,Akiko Sekiguchi,Sayaka Toki,Chikako Kishi,Yukie Endo,Masahito Yasuda,Hidekazu Ikeuchi,Toru Sakairi,Kenichiro Hara,Koichi Yamaguchi,Toshitaka Maeno,Keiju Hiromura,Osamu Ishikawa

DOI: https://doi.org/10.1684/ejd.2019.3634

2019-10-01

European Journal of Dermatology

Abstract:BackgroundAnti-melanoma differentiation-associated gene 5 (MDA5) antibody has been recognized to be significantly associated with a subset of dermatomyositis patients with rapidly progressive interstitial lung disease (RP-ILD).ObjectivesTo elucidate the clinical characteristics and poor prognostic factors in Japanese dermatomyositis patients with anti-MDA5 antibody.Materials and methodsClinical features of anti-MDA5 antibody-positive dermatomyositis patients and risk factors, potentially associated with a poor prognosis, were retrospectively analysed.ResultsA total of 37.3% (28/75) dermatomyositis patients were positive for anti-MDA5 antibody. The frequency of Gottron’s papules, palmar violaceous macules, antihelix/helix violaceous macules, and clinically amyopathic dermatomyositis (CADM) was significantly higher in patients with anti-MDA5 antibody. Of anti-MDA5 antibody-positive dermatomyositis patients, 57.1% developed RP-ILD, and in those with RP-ILD, serum ferritin level was markedly high and partial pressure of arterial oxygen (PaO2) was significantly low at first visit. Among patients with anti-MDA5 antibody with RP-ILD, non-survivors were older and revealed lower PaO2 at first visit relative to survivors. Furthermore, patients who did not take triple therapy (prednisolone, calcineurin inhibitor and cyclophosphamide) as initial treatment resulted in poor outcome.ConclusionAnti-MDA5 antibody may be associated with CADM, the progression to RP-ILD, high serum ferritin level, and characteristic skin manifestations. High serum ferritin level in patients with anti-MDA5 antibody may be associated with the development of RP-ILD and poor prognosis. Early treatment with triple therapy, including intravenous cyclophosphamide, may improve the prognosis of RP-ILD.

dermatology
Clinical utility of anti-Ro52 antibody confirmation in anti-MDA5 antibody-positive dermatomyositis: A case report

Hitoshi Kodera,Reina Hirano,Masahiro Akiyama,Yoshifuji Matsumoto

DOI: https://doi.org/10.1093/mrcr/rxae027

2024-07-08

Abstract:This case report highlights dermatomyositis (DM) characterised by the concurrent presence of anti-melanoma differentiation-associated protein 5 (anti-MDA5) and anti-Ro52 antibodies. A 64-year-old woman initially presented with erythema on the palms, which later spread to the dorsum of the hands, followed by involvement of the face, forehead, and upper eyelids. The patient reported joint pain, fatigue, and dyspnea. Physical examination revealed characteristic cutaneous manifestations, including heliotrope rash and Gottron's sign, accompanied by skin ulceration and muscle weakness. Blood tests showed elevated levels of creatine phosphokinase and C-reactive protein. A high-resolution computed tomography (HRCT) scan revealed interstitial lung disease (ILD) with an organising pneumonia (OP) pattern. Magnetic resonance imaging (MRI) confirmed the presence of myositis. Autoantibody analysis revealed concurrent positivity for both anti-MDA5 and anti-Ro52 antibodies. At the time of diagnosis, she had no respiratory impairment, but had an elevated C-reactive protein and high levels of anti-MDA5 antibody. She was started on triple combination therapy with glucocorticoids, cyclophosphamide, and tacrolimus. She had worsening oxygenation and elevated ferritin during the first weeks of treatment, but then her symptoms improved. Early detection of a co-positive anti-Ro52 antibody led to early initiation of triple combination therapy and a good prognosis.
Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis

Hideaki Tsuji,Ran Nakashima,Yuji Hosono,Yoshitaka Imura,Masato Yagita,Hajime Yoshifuji,Shintaro Hirata,Takaki Nojima,Eiji Sugiyama,Kazuhiro Hatta,Yoshio Taguchi,Masaki Katayama,Kiminobu Tanizawa,Tomohiro Handa,Ryuji Uozumi,Shuji Akizuki,Kosaku Murakami,Motomu Hashimoto,Masao Tanaka,Koichiro Ohmura,Tsuneyo Mimori

DOI: https://doi.org/10.1002/art.41105

2020-01-27

Abstract:<h3 class="article-section__sub-title section1"> Objective</h3><p>Interstitial lung disease (ILD) accompanied by anti‐melanoma differentiation‐associated gene 5 (MDA5)‐positive dermatomyositis (DM) is often rapidly progressive and associated with poor prognosis. Because there is no established treatment, we prospectively evaluated the efficacy and safety of a combined immunosuppressive regimen for anti‐MDA5‐positive DM with ILD.</p><h3 class="article-section__sub-title section1"> Methods</h3><p>Adult Japanese patients with newly onset anti‐MDA5‐positive DM with ILD (n = 29) were enrolled in multiple centers from 2014 to 2017. They were treated with a regimen of high‐dose glucocorticoids (GC), tacrolimus, and intravenous cyclophosphamide (IVCY). Plasmapheresis was used if patients worsened after the regimen started. The primary endpoint was six‐month survival, compared with that of a historical control (n = 15) of patients with anti‐MDA5‐positive DM with ILD who received step‐up treatment (high‐dose GC and stepwise addition of immunosuppressant). Secondary endpoints were 12‐month survival rate, adverse events, and changes in laboratory data.</p><h3 class="article-section__sub-title section1"> Results</h3><p>The combined immunosuppressive regimen group showed significantly higher 6‐month survival than the step‐up treatment group (89% and 33%, respectively, P < 0.0001). Over 52 weeks, anti‐MDA5 titer, serum ferritin level, percent vital capacity, and chest high‐resolution computed tomography scores improved. The combined immunosuppressive regimen group received IVCY nearly 20 days earlier with shorter intervals and tended to receive plasmapheresis more often than patients undergoing step‐up treatment (n = 15). Cytomegalovirus reactivation was frequently observed over 52 weeks.</p><h3 class="article-section__sub-title section1"> Conclusion</h3><p>A combined immunosuppressive regimen is effective for anti‐MDA5‐positive DM with ILD. Plasmapheresis can be used for additional effect in intractable disease. Opportunistic infections should be carefully monitored during treatment.</p>

rheumatology
MDA5 Expression is Associated with TGF-β-induced Fibrosis: Potential Mechanism of Interstitial Lung Disease in Anti-Mda5 Dermatomyositis.

Ning Shen,Xiaopeng Zhou,Xuexiao Jin,Ci Lu,Xiuhua Hu,Yichi Zhang,Yu Jiang,Qin Xu,Xiayan Xu,Minghao Liu,Linrong Lu,Yongmei Han

DOI: https://doi.org/10.1093/rheumatology/keac234

2022-01-01

Rheumatology

Abstract:Objectives This study aimed to investigate the high-resolution CT (HRCT) characteristics of anti-melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis-associated interstitial lung disease (anti-MDA5 DM-ILD), and to clarify the underlying mechanisms of the clinical phenomenon. Methods Clinical data and HRCT patterns were compared between anti-MDA5 DM-ILD (n = 32) and antisynthetase syndrome-associated ILD (ASS-ILD) (n = 29). RNA sequencing of whole-blood samples from the two groups, and in vitro experiments using human embryonic lung fibroblasts (HELFs) were conducted to explore the potential mechanisms of the clinical findings. Results The anti-MDA5 DM-ILD subset had a significantly higher incidence of rapidly progressive ILD (RPILD) than ASS-ILD (65.6% vs 37.9%; P = 0.031). The relative percentage of the lung fibrosis HRCT pattern was significantly lower in the anti-MDA5 DM-ILD group, especially the RPILD subgroup (P = 0.013 and 0.003, respectively). RNA sequencing detected the upregulated genes including interferon-induced helicase C domain 1 (encoding MDA5), and a trend towards downregulated expression of TGF-beta signalling components in anti-MDA5 DM-ILD. In vitro culture of HELFs revealed that upregulated expression of MDA5 in HELFs was correlated with the downregulated expression of alpha smooth muscle actin, connective tissue growth factor, collagen I and collagen III by suppressing the TGF-beta signalling pathway. Conclusions Anti-MDA5 DM-ILD patients have significantly less lung fibrosis and elevated MDA5 expression. The upregulated expression of MDA5 has relations with the suppression of the pro-fibrotic function of fibroblasts via the TGF-beta signalling pathway, which may partially explain the mechanism of the clinical phenomenon.
Examination of prognostic factors in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis

Suzuna Sugi,Masaki Tominaga,Shinjiro Kaieda,Kiminori Fujimoto,Tomonori Chikasue,Takuma Koga,Yuri Hasuo,Erina Iwanaga,Kenta Murotani,Jamie Kristen T Lim,Hiroaki Ida,Tomotaka Kawayama,Tomoaki Hoshino

DOI: https://doi.org/10.1093/mr/roae007

2024-02-01

Modern Rheumatology

Abstract:ABSTRACT Objective This study investigated the prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM). Methods This study analysed 34 MDA5-DM cases (20 and 14 in the survival and death groups, respectively) encountered at Kurume University between 2008 and 2021. The clinical, physiological, and computed tomography findings, pulmonary function, and serological results were retrospectively evaluated for each MDA5-DM case during the first visit and throughout the next 12 weeks. Results In the death group, the mean age of patients was higher (47.6 vs. 61.8 years), while the duration from symptom onset to consultation was shorter (110 vs. 34.9 days). During the first visit, the death group demonstrated a significantly higher serum C-reactive protein level (0.52 vs. 1.99) and a significantly lower albumin level (3.23 vs. 2.63) than the survival group; this persisted throughout the next 12 weeks. Poor prognosis was associated with C-reactive protein and albumin levels >0.19 mg/dl and <2.3 g/dl, respectively, 4 weeks after starting the treatment. Conclusion Four weeks after starting the treatment, serum C-reactive protein and albumin levels of patients with MDA5-DM can be used to evaluate treatment response and predict prognosis.

rheumatology
Assessing Time of Onset for Interstitial Lung Disease in Anti-MDA5 Antibody-Positive Dermatomyositis

Rachel R. Lin,Peyton V. Warp,Andrea D. Maderal,Scott A. Elman

DOI: https://doi.org/10.1001/jamadermatol.2024.0507

IF: 11.816

2024-04-10

JAMA Dermatology

Abstract:This cohort study seeks to describe the time interval between interstitial lung disease and anti–melanoma differentiation-associated gene 5 antibody-positive dermatomyositis diagnoses.

dermatology
Anti-MDA5 and anti-SSA/Ro52 antibodies double-positive dermatomyositis overlapping with rheumatoid arthritis-associated interstitial lung disease: A case report

Hong Xiong,QianRen Tan,Feng Luo,XueMei Yuan,Wukai Ma,XueMing Yao

DOI: https://doi.org/10.1111/1756-185X.14430

Abstract:Dermatomyositis (DM) is a poorly prognostic autoimmune disease the pathogenesis of which is multifactorial and not clearly defined. DM may be influenced by genes, environment, and immunity. The typical manifestations of DM are Gottron rash, heliotrope rash, rash on the shoulders and buttocks, erythema around fingernails, excessive keratosis of the epidermis, mechanic's hands, and interstitial lung disease (ILD), among others. Anti-melanoma differentiation-associated 5 gene (MDA5) antibody has been strongly associated with DM. Furthermore, anti-SSA/Ro52 antibody has been reportedly associated with DM. A 49-year-old woman presented with cough, expectoration, and dyspnea. Relevant examinations revealed elevated levels of muscle enzyme, double-positive anti-MDA5 and anti-SSA/Ro52 antibodies, positive rheumatoid factor, and a high titer of anti-citrullinated protein antibody. DM overlapping rheumatoid arthritis with ILD was confirmed. We suggest the use of glucocorticoids combined with immunosuppressant therapy, supplemented with gastric and liver protection, and recommend the use of intravenous immunoglobulins and rituximab.
Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease

Fang-Ping Ren,Qi Chen,Shan-Shan Yao,Lin Feng,Xin-Ying Xue,Wei-Chao Zhao,Dong Wang,Zhi-Ling Zhao,Si-Wei Gu,Ting Li,Ya-Wen Shen,Lan Gao,Xue-Lei Zang,Xin-Yu Bao,Zhao-Hui Tong

DOI: https://doi.org/10.1186/s12890-023-02706-y

IF: 3.1

2023-10-30

BMC Pulmonary Medicine

Abstract:To examine the characteristics of blood lymphocyte subsets in dermatomyositis-interstitial lung disease (DM-ILD) inflicted patients with positive anti-melanoma differentiation-associated gene 5 (anti-MDA5), as well as its prognosis value in this set of patients.

respiratory system
[Anti-MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia]

Ran Nakashima,Tsuneyo Mimori

DOI: https://doi.org/10.2177/jsci.36.71

Abstract:Anti-MDA5 antibody is one of the dermatomyositis-specific autoantibodies and anti-MDA5-potsitive patients show characteristic clinical features, such as hypomyositis, high prevalence of acute/subacute interstitial pneumonia (A/SIP) with poor prognosis, hyperferritinemia and elevated hepatobiliary enzyme. We found that serum IL-6, IL-18, M-CSF and IL-10 were significantly higher and serum IL-12 and IL-22 were significantly lower in anti-MDA5-positive patients than in anti-MDA5-negative patients before treatment. Taking together these serological findings, we hypothesized that monocyte and macrophage activation may underlie in the pathophysiology of anti-MDA5-positive patients. They rarely survive after they become to need oxygenation, and so need to be treated as soon as possible once the diagnosis has been made. Intensive regimen of combined immunosuppressive therapy (high-dose corticosteroids, oral cyclosporin and intravenous cyclophosphamide (IVCY, 900-1000 mg/m(2) in every other week)) improved the survival rate of anti-MDA5-positive patients. Especially, the serum ferritin levels tended to go down about 14 days after IVCY, suggesting that IVCY might be a key drug in the treatment of anti-MDA5-positive A/SIP patients.
Profile of patients with Juvenile Dermatomyositis and Anti-MDA5 autoantibodies

Pandiarajan Vignesh,Pallavi L. Nadig,Suprit Basu,Shravani Reddy,Reva Tyagi,Aditya Dod,Rajni Kumrah,Ravinder Garg,Saniya Sharma,Manpreet Dhaliwal,Rakesh Kumar Pilania,Ankur Jindal,Deepti Suri,Amit Rawat,Surjit Singh

DOI: https://doi.org/10.1038/s41390-024-03551-3

IF: 3.953

2024-09-25

Pediatric Research

Abstract:Anti–MDA5 autoantibody-positive dermatomyositis (MDA5-DM) is associated with clinically amyopathic forms and rapidly progressive interstitial lung disease (ILD); however, data in children are limited. In this study, we described our cohort of anti-MDA5-positive juvenile DM (MDA5-JDM) from a tertiary care center in North India.

pediatrics
Antimelanoma differentiation antigen 5-positive dermatomyositis: an update

Xin Lu,Qinglin Peng,Guochun Wang

DOI: https://doi.org/10.1097/bor.0000000000001034

2024-07-16

Current Opinion in Rheumatology

Abstract:Purpose of review Antimelanoma differentiation antigen 5-dermatomyositis (MDA5-DM) is a complex and serious systemic autoimmune disease that primarily affects the skin and lungs. In this review, we aimed to provide new insights into the clinical features, pathogenesis, and practical management approach for this disease. Recent findings Although lung lesions are prominent in most patients with MDA5-DM, they are now recognized as heterogeneous diseases. Peripheral blood lymphocyte count can serve as a simple and reliable laboratory parameter for categorizing MDA5-DM into three subgroups: mild, medium, and severe. Recent studies have implicated viral infection, genetic factors, autoimmunity against MDA5, multiple immune cells, and interferons as significant contributors to MDA5-DM pathogenesis. In addition to traditional treatments with glucocorticoids and immunosuppressants, many new approaches, including new biologics and targeted agents, have been explored. Additionally, infection is a common complication of MDA5-DM, and prophylaxis or treatment of the infection is as important as treating the primary disease. Summary Knowledge of clinical characteristics and pathogenesis of MDA5-DM has grown in recent years. Although many new therapeutic approaches have been explored, further studies are required to confirm their efficacy.

rheumatology

Hospitalization and Continuity of Care in Anti-MDA5 Dermatomyositis

Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review

Unique Characteristics of Anti-MDA-5 Associated Dermatomyositis in Southern California with a Large Hispanic Population

Patient Perspectives of the Manifestations and Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis: An Observational Survey

Anti‐MDA5 positivity: describing the frequency and spectrum of clinically evident MDA5 disease

Short-term and long-term outcomes of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis

Clinical features of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with macrophage activation syndrome

Characteristics of anti-melanoma differentiation associated gene 5 antibody-positive dermatomyositis with thrombotic microangiopathy

Treatment strategies in MDA5-positive clinically amyopathic dermatomyositis: a single-center retrospective analysis

Myocardial involvement is not rare in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis/clinically amyopathic dermatomyositis: a retrospective study

Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease

Clinical utility of anti-Ro52 antibody confirmation in anti-MDA5 antibody-positive dermatomyositis: A case report

Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis

MDA5 Expression is Associated with TGF-β-induced Fibrosis: Potential Mechanism of Interstitial Lung Disease in Anti-Mda5 Dermatomyositis.

Examination of prognostic factors in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis

Assessing Time of Onset for Interstitial Lung Disease in Anti-MDA5 Antibody-Positive Dermatomyositis

Anti-MDA5 and anti-SSA/Ro52 antibodies double-positive dermatomyositis overlapping with rheumatoid arthritis-associated interstitial lung disease: A case report

Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease

[Anti-MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia]

Profile of patients with Juvenile Dermatomyositis and Anti-MDA5 autoantibodies

Antimelanoma differentiation antigen 5-positive dermatomyositis: an update